EpigenCare The Best First Skin Care Solution In The World

What is EPIGENCARE?

EpigenCare is the world's first biotechnology company for personalized skincare by combining epigenetic technology and blockchain technology

EpigenCare provides personalized skin care statistics through evaluation of epigenetic characters of consumer DNA samples. With the next generation of sequencing techniques, we will be able to truly feel the consumer's dynamic skin home for a convincing skincare. Through blockchain technology, we can maintain protective anonymity while allowing transparency how their records are used fully and simultaneously for their own benefit in a structured ecosystem. Furthermore, it gives us accumulated records to be commoditized (tokenized), leveraged, and commercially used by skin care-related businesses in a smart, personalized, and accountable way.

The skin care market offers very large and confusing product determination. Although many of these products claim to have a scientific substance to the mechanism (eg anti-aging, bright pores and skin, moisture retention, wrinkle tightness, etc.), consumer spending for choice often depends on non-scientific elements such as flashy advertising, loyalty manufacturers, referrals, social media influencers, and customer reviews.


Aim

1. To give consumers a regularly updated skin care profile and suggest personalized routines and / or skincare products.

2. To increase the revenue of solution providers, retailers, and skincare manufacturers by delivering intelligent and measurable consumer profile care consumer profiles and predictive consumer purchasing desires.

3. To create an updated skin care profile data profile through intelligent cryptographic blockfain contract technology

4. To enable transparent use of consumer data without disclosing identifiable information through blockchain to eliminate the perceived privacy intrusibility of personalization.

5. To be the starting point for the desired market data related to epigenetically measurable skin care

Problem

The skin care market offers an enormous and often confusing product selection. Although many of these products claim to have a scientific substance to the mechanism (eg anti aging, skin lightening, moisture retention, wrinkle tightness, etc.), consumer purchase decisions often depend on non-scientific factors such as flashy advertising, brand loyalty, social influencers, and consumer reviews. However, there is always the customer's inherent doubt about whether the selected product works as claimed, encouraging constant search for the ideal product that matches the features of its skin.

Solution

We aim to facilitate major changes in the purchasing decision process - from push manufacturer / retailer methods to skin care products to consumer pull methods. A two-part solution is proposed:

First, we will offer personalized skincare tests to consumers who will test the epigenetic profile of a person's skin, allowing us to recommend the ideal product choices to consumers. This recommendation is based on the correlation between the epigenetic mechanism of the product functional ingredient and the epigenetic profile of the consumer responsible for various skin features.

we will strive for blockchain science for anonymous companion information with consumers and apply incentive mannequins for routine tests.

Introducing EPIC token

The sale of pre-launch tokens, also recognized as Initial Coin Offering (ICO), was awarded at the end of Q1 2018 due to the skill to spread entry to tokens to the market extensively. In addition, it serves to produce results as the most important ability to bring EpigenCare to the market. EPIC tokens will be purchased with ETH (Ethereal) and will be delivered to clients within approximately six weeks after ICO completion.

Because EPIC tokens are constantly available and function as transactional gadgets access to the EpigenCare Network, the market value of each EPIC will doubtfully increase as there is an increased demand for data. Larger demand, more tokens will be used in EpigenCare Networks, returning them back into the running EpigenCare wallet. It spends the token on the market and creates an impact of scarcity because they need to be in a repurchased round track through additional testing or record sales.

The growing cost of existing EPIC prices in expanding its purchasing power against (a) the fact of purchase for the Applicant; and (b) offset the price of skin care for consumers. Since each EPIC can be split into the 18th decimal point, we can prevent impractical purchases volumes by consumers or Applicants should EPIC substantially increase market value.

Token Sale

Ticker Symbol: EPIC

Type: ERC20

Initial Value: 1 EPIC = $ 0.40

Minimum Contribution: $ 500

Crowdsale Supply: 50,000,000

Number of Supply: 100,000,000

Hard Cap: $ 20,000,000

Roadmap

Team Member

1. William Lee,

Chief Executive Officer William Lee is an entrepreneur with more than 10 years experience in biotechnology and entertainment. He is currently a shareholder and senior executive of EpiGentek Group Inc., a biotechnology reagent company specializing in epigenetics, and has previously set up music licensing and game businesses. He has significant experience in the management, operations, web development, and marketing of B2B and B2C. With a passion for disruptive technology, he invested in Bitcoin in 2013 and then Ethereum in his early days. William Lee studied at New York University and Carnegie Mellon University. While pursuing an MBA at the Carnegie Mellon Tepper School of Business,

2. Adam Weiwei Li, MD, Ph.D.,

Chief Scientific Officer Adam Li is the scientific founder and CSO of EpiGentek Group, Inc. who has more than 20 years of experience in oncology and pharmacology and 15 years of experience in epigenetic research. He pioneered the development of epigenetic-based cancer markers, detection tests, and research products. The publication list includes 46 peer-reviewed papers in the field of cancer and epigenetics. As the first inventor, he has filed 11 patent applications related to epigenetic test methods and medical cosmetics, in which 4 patents were issued. Dr. Li completed his postdoctoral training at Memorial Sloan-Kettering Cancer Center and served as a doctoral biologist at Memorial Hospital in New York before joining EpiGentek.

3. Jessica Li,

Chief Financial Officer Jessica has more than 20 years of experience in accounting, finance, banking, and business management. He is co-founder and CFO of EpiGentek Group, Inc. in which he develops and facilitates financial strategies, budgeting and cost management, and accounting operations to ultimately increase the overall value of the company. Prior to joining EpiGentek, he worked in several BPA companies as well as in the banking sector in New York. He holds a bachelor's degree in finance and an MBA from the New York Institute of Technology School of Management with a concentration in accounting

4. Ashley Pottash,

Business Development Lead Ashley Pottash is a strategic and creative brand builder with over 8 years experience in the fashion and beauty industry. She specializes in visual merchandising for luxury brands and is Senior Manager of Global Visual Merchandising in Coty, Inc. for the perfumes of Marc Jacobs and Calvin Klein. Ashley serves as Manager of Merchandise Development and Purchasing at CHANEL for all makeup, skin care, and selling point of sales. After leaving CHANEL, she pioneered visual merchandising and store design for innovative beauty care and skincare brands, Charlotte Tilbury. Ashley graduated earlier than the Robins School of Business at the University of Richmond with a focus on business and marketing.

5. Stephen Fiser,

Software Development Stephen Fiser is a software engineer specializing in blockchain, Solidity, and dApps technologies. After graduating from the University of Arkansas with a degree in biophysics, Stephen works in the enterprise information technology sector. Wanting to focus on new technology, he moved to New York City and shifted his gears to work with startup companies until 2014 when he founded Blue Bear Digital Inc., a full software development agency

6. Richard Wildnauer, Ph.D.,

Business Adviser Dr. Richard Wildnauer has more than 30 years of experience in the dermatological, cosmeceutic, and pharmaceutical industries. He is a former CEO of NeoStrata and works for Johnson & Johnson's senior executive position and VP of Skin Care and Business Development at J & J Corporate. He established RHW Associates LLC to provide strategic and operational advice to the Board and CEO of entrepreneurial entrepreneurship and health care companies based on extensive industry career experiences ranging from R & D directors to Presidents / CEOs to Board Leaders. In addition, he previously served as Chairman of the Board of EuroMed, Inc. and currently serves as Director of the Board at Dynamis Skin Sciences. Dr. Wildnauer holds a Ph.D. in Biochemistry from West Virginia University and an MBA from Rider University.

7. James Wang, MD,

Dermatologist Dr. James Y. Wang is a board certified dermatologist and dermatopath who is undergoing clinical practice in Beverly Hills, California. He is currently CEO of Curebiotech, Inc., a Philadelphia-based biotechnology startup that focuses on stem cell therapy and immunity for skin diseases and metastatic cancer. Wang received the MD and MBA from Harvard, and was trained at other prestigious institutions including UCLA, Memorial Sloan Kettering Cancer Center, and New Presbyterian Hospital.

8. Brennan Bennett,

Blockchain Advisor Brennan is co-founder and COO of QBRICS, Inc. and the Founder of Blockchain Healthcare Review. He is an experienced health information technology (HIT) strategist who holds an MS degree in Biomedical Informatics from Rutgers School of Health Professions and has a professional background as a corporate strategy consultant in the pharmaceutical business line. Brennan is currently involved in blockchain chambers as advisers, consultants, publicists, columnists and co-contributors of some proprietary blockchain technologies.

9. Rebecca Fry, Ph.D.,

Epigenetic Advisor Dr. Rebecca Fry is Carol Remmer Angle Distinguished Professor and Associate Chair of the Department of Environmental Science and Engineering at the Gillings School of Global Public Health at UNC-Chapel Hill. Dr. Fry is the principal investigator of several NIH funded multi-million dollar grants. He is the Director of the T32 Environmental Health Sciences Training Graduate and Director of Postgraduate Studies in the Toxicology Curriculum. Dr. Fry holds a Ph.D. in biology with postdoctoral training in toxicogenomics and environmental health sciences. His research at UNC has identified an epigenetic mechanism linking toxic substances with the health of children. He has served on the National National Sciences of Science (NAS) committee of the National Research Council to review IRIS inorganic arsenic,

10. Tim Bukher,

Legal Strategy Counsel Tim Bukher is a legal counsel and founding partner of Thompson Bukher LLP, representing investment funds and technology startups in securities, venture capital, and corporate issues. The Team's background and national recognition as an information technology specialist have brought practice to the forefront of legal development in blockchain and cryptocurrency. The team also makes use of its experience in the capital and venture sectors to be a direct advisor to many companies in the blockroom. Most recently, he served as a US legal counselor in the highly successful SingularityNET crowd. The team received a JD degree from Benjamin N. Cardozo School of Law, and he earned a degree in Economics from New York University.

Further information can be found through the links that I include below:

Website 

ICO 

Whitepaper 

Twitter 

Facebook 

Telegram

My profile: https://bitcointalk.org/index.php?action=profile;u=926621